- Home
- SUPN vs KROS Comparison
SUPN vs KROS Comparison
Compare SUPN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- KROS
- Stock Information
- Founded
- SUPN 2005
- KROS 2015
- Country
- SUPN United States
- KROS United States
- Employees
- SUPN N/A
- KROS N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- SUPN Health Care
- KROS Health Care
- Exchange
- SUPN Nasdaq
- KROS Nasdaq
- Market Cap
- SUPN 2.6B
- KROS 565.0M
- IPO Year
- SUPN 2012
- KROS 2020
- Fundamental
- Price
- SUPN $43.99
- KROS $15.55
- Analyst Decision
- SUPN Buy
- KROS Buy
- Analyst Count
- SUPN 2
- KROS 14
- Target Price
- SUPN $43.00
- KROS $20.56
- AVG Volume (30 Days)
- SUPN 602.3K
- KROS 417.3K
- Earning Date
- SUPN 11-03-2025
- KROS 11-05-2025
- Dividend Yield
- SUPN N/A
- KROS N/A
- EPS Growth
- SUPN 1411.53
- KROS N/A
- EPS
- SUPN 1.14
- KROS 0.47
- Revenue
- SUPN $665,125,000.00
- KROS $232,844,000.00
- Revenue This Year
- SUPN $4.84
- KROS $5,579.44
- Revenue Next Year
- SUPN $17.69
- KROS N/A
- P/E Ratio
- SUPN $38.61
- KROS $33.52
- Revenue Growth
- SUPN 5.55
- KROS 85820.30
- 52 Week Low
- SUPN $29.16
- KROS $9.12
- 52 Week High
- SUPN $46.79
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- SUPN 53.82
- KROS 57.26
- Support Level
- SUPN $45.26
- KROS $15.23
- Resistance Level
- SUPN $46.72
- KROS $15.85
- Average True Range (ATR)
- SUPN 1.09
- KROS 0.48
- MACD
- SUPN -0.39
- KROS -0.01
- Stochastic Oscillator
- SUPN 7.28
- KROS 65.55
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.